Kennedy-Wilson (KW) investor relations material

Executive summary

• Achieved GAAP net income attributable to common shareholders of $13.7 million for Q1 2026, reversing a $40.8 million loss in Q1 2025, driven by fair value gains, acquisition-related gains, and higher investment management fees.

• Adjusted EBITDA rose 44% year-over-year to $141.8 million, reflecting improved operating performance and lower carried interest reversals.

• Announced a take-private merger agreement with affiliates of Fairfax Financial and certain stockholders, with a special shareholder meeting scheduled for June 10, 2026.

• Investment management platform fees increased 11% to $28 million, with fee-bearing capital reaching $11.2 billion.

• Portfolio activity included $333 million deployed or committed, $251 million in new loan originations, and $90 million cash generated from dispositions.

Financial highlights

• Total revenue was $117.2 million, down from $128.3 million in Q1 2025, mainly due to asset sales and deconsolidations.

• Net income attributable to common shareholders was $13.7 million, or $0.10 per diluted share, compared to a loss of $40.8 million, or $(0.30) per share, in Q1 2025.

• Adjusted net income was $50.5 million, up from an adjusted net loss of $0.7 million year-over-year.

• Estimated annual NOI as of Q1 2026 is $425 million.

• Cash and cash equivalents stood at $185 million, with $368 million drawn on a $550 million credit facility.

Outlook and guidance

• Management expects continued growth in investment management fees and a shift toward lower ownership levels in new loan originations, resulting in higher fee income but lower interest income.

• Estimated annual NOI guidance remains at $425 million, with fee-bearing capital expected to continue growing.

• The company anticipates repaying or offering to repay all outstanding senior unsecured notes in connection with the merger.

• Ongoing macroeconomic volatility, including inflation, interest rates, and capital market liquidity, may impact future results.